Teva' said that its product is an alternative to the brand product, which had annual sales of approximately $293 million in the United States for the twelve months that ended June 30, based on IMS sales data.
As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity in the U.S.
Teva is distributing the product, under a license agreement entered into between Teva's subsidiary Barr Pharmaceuticals, Inc. and sanofi-aventis U.S. Allegra-D is a registered trademark of sanofi-aventis U.S.
Teva Pharmaceutical Industries, headquartered in Israel, is a generic pharmaceutical company.
((Comments on this story may be sent to health@closeupmedia.com))

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index